Insider Selling: ASP Isotopes (NASDAQ:ASPI) Director Sells $649,186.08 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) Director Todd Wider sold 74,108 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $8.76, for a total value of $649,186.08. Following the transaction, the director directly owned 710,230 shares in the company, valued at $6,221,614.80. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

ASP Isotopes Price Performance

NASDAQ ASPI opened at $9.34 on Monday. The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56. The stock has a market capitalization of $858.47 million, a price-to-earnings ratio of -15.31 and a beta of 3.29. ASP Isotopes Inc. has a 1-year low of $2.78 and a 1-year high of $11.86. The business’s fifty day moving average price is $9.53 and its 200-day moving average price is $7.78.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The company had revenue of $1.20 million during the quarter, compared to analysts’ expectations of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. On average, equities analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Saturday, September 27th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research note on Wednesday, September 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $11.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its position in ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after acquiring an additional 1,600 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in ASP Isotopes by 9.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock worth $153,000 after acquiring an additional 1,878 shares in the last quarter. Bank of Montreal Can grew its position in ASP Isotopes by 8.0% in the second quarter. Bank of Montreal Can now owns 27,000 shares of the company’s stock worth $199,000 after acquiring an additional 2,000 shares in the last quarter. Rathbones Group PLC grew its position in ASP Isotopes by 1.1% in the second quarter. Rathbones Group PLC now owns 208,149 shares of the company’s stock worth $1,532,000 after acquiring an additional 2,220 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.